-transparent.png){kind=logo}
The goal of cancer immunotherapy is to achieve cure when the more usual means of treatment fail to do so. This can be achieved in some animal models where tumor rejection antigens have been demonstrated. In man, the contribution of immunotherapy to the treatment of minimal residual but disseminated disease has been exceedingly poor. This discrepancy should be analyzed, in an effort to detect and define in vitro putative tumor rejection antigens in human tumors.
Related Publications
B Chapuis, and
L Barrelet, and
J Dialdas
August 1968,
Wiener klinische Wochenschrift,
B Chapuis, and
L Barrelet, and
J Dialdas
August 1968,
Wiener klinische Wochenschrift,
B Chapuis, and
L Barrelet, and
J Dialdas
January 1966,
Strahlentherapie. Sonderbande,
B Chapuis, and
L Barrelet, and
J Dialdas
August 2020,
Der Radiologe,
B Chapuis, and
L Barrelet, and
J Dialdas
May 1972,
Das Deutsche Gesundheitswesen,
B Chapuis, and
L Barrelet, and
J Dialdas
January 1980,
Terapevticheskii arkhiv,
B Chapuis, and
L Barrelet, and
J Dialdas
April 1978,
Medizinische Klinik,
B Chapuis, and
L Barrelet, and
J Dialdas
May 1991,
Vrachebnoe delo,
B Chapuis, and
L Barrelet, and
J Dialdas
April 1973,
Minerva medica,
B Chapuis, and
L Barrelet, and
J Dialdas
December 1978,
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
